AIM ImmunoTech Inc. (NYSE American: AIM) has commenced its Phase 2 study to evaluate the potential therapeutic effects of Ampligen® on individuals with post-COVID conditions. The enrollment and dosing of the first subject have already taken place, with encouraging preliminary data on Ampligen. The study is projected to be fully enrolled by Q4 2023.
In order to facilitate this study, AIM has established multiple clinical research sites and has conducted screenings for numerous potential participants. The screening process is currently ongoing, and additional subjects will be administered doses of Ampligen in the following weeks. The ultimate objective of this research is to develop Ampligen as a treatment option for Long COVID patients experiencing chronic fatigue-like symptoms, thereby addressing a significant unmet medical need.
Long COVID poses substantial challenges for patients, caregivers, and families alike. According to the CDC, approximately 1.6% of adults in the U.S. are grappling with activity limitations resulting from Long COVID.